semaglutide obesity phase 3 Transforming obesity: The advancement of multi-receptor drugs: Cell Current clinical application of incretin

Inherited and acquired blood disorders, such as sickle-cell anemia, glucose-6-phosphate dehydrogenase deficiency, and paroxysmal nocturnal hemoglobinuria [23]

The demographic distribution of those most likely to stop treatment was as follows: patients of color, men, people enrolled in Medicare or Medicaid, those living in areas with very high social needs, heart failure, obesity or other cardiovascular diseases prior to drug initiation, and those experiencing new gastrointestinal adverse effects at follow-up [132]

Men often deal with stress, irregular sleep, and pollution exposure that can affect both skin and stamina

Weight loss is secondary to maintaining muscle mass, nutritional status, and autonomy

That said, both are considered effective, with similar response ratesmeaning that most people will lose weight on either drug

There are reports of acute kidney injury in at-risk patients